牛牛AI助手已提取核心信息
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on 02/15/2024, according to a recent filing. The shares, valued at an aggregate market value of $1,607,176, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This planned sale follows a three-month period where Kulkarni sold 70,000 shares, generating gross proceeds of $4,275,626.
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on 02/15/2024, according to a recent filing. The shares, valued at an aggregate market value of $1,607,176, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This planned sale follows a three-month period where Kulkarni sold 70,000 shares, generating gross proceeds of $4,275,626.
最近的一份文件显示，同时担任高管兼董事的CRISPR Therapeutics高管萨玛斯·库尔卡尼定于2024年2月15日出售2万股普通股。这些股票的总市值为1,607,176美元，于当天通过行使股票期权收购，该交易涉及向发行人支付现金。此次计划出售是在库尔卡尼在三个月内出售了7万股股票之后进行的，总收益为4,275,626美元。
最近的一份文件显示，同时担任高管兼董事的CRISPR Therapeutics高管萨玛斯·库尔卡尼定于2024年2月15日出售2万股普通股。这些股票的总市值为1,607,176美元，于当天通过行使股票期权收购，该交易涉及向发行人支付现金。此次计划出售是在库尔卡尼在三个月内出售了7万股股票之后进行的，总收益为4,275,626美元。
有用
没用